The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced has approved the medicine sotatercept, Winrevair, to treat pulmonary arterial hypertension. The new marketing authorization was granted on December 27 to Merck (MRK) Sharp & Dohme Limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Nike downgraded, FedEx upgraded: Wall Street’s top analyst calls
- BTIG reiterates Buy on Viking Therapeutics after Novo’s CagriSema ‘underwhelms’
- Personalis price target raised to $8 from $7 at BTIG